当前位置: 首页 >> 检索结果
3981. Angiotensin receptor blockade is associated with increased risk of giant cell arteritis.
作者: Sizheng Steven Zhao.;Houchen Lyu.;Chao Zeng.;Guanghua Lei.;Jie Wei.;Sarah L Mackie.
来源: Rheumatology (Oxford). 2023年62卷6期2203-2210页
Angiotensin II is implicated in GCA pathology. We examined whether the use of angiotensin receptor blockers (ARBs) is associated with GCA risk compared with angiotensin-converting enzyme inhibitors (ACEis) or other antihypertensives.
3982. Citrullinated and carbamylated proteins in extracellular microvesicles from plasma of patients with rheumatoid arthritis.
作者: Federica M Ucci.;Serena Recalchi.;Cristiana Barbati.;Valeria Manganelli.;Antonella Capozzi.;Gloria Riitano.;Giorgia Buoncuore.;Tina Garofalo.;Fulvia Ceccarelli.;Francesca R Spinelli.;Eugenia Balbinot.;Alessandra Ida Celia.;Agostina Longo.;Cristiano Alessandri.;Roberta Misasi.;Maurizio Sorice.;Fabrizio Conti.
来源: Rheumatology (Oxford). 2023年62卷6期2312-2319页
To investigate the expression of citrullinated and carbamylated proteins in extracellular microvesicles (EMVs) from RA patients.
3983. Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study.
作者: Karin Wadström.;Lennart T H Jacobsson.;Aladdin J Mohammad.;Kenneth J Warrington.;Eric L Matteson.;Magnus E Jakobsson.;Carl Turesson.
来源: Rheumatology (Oxford). 2023年62卷6期2304-2311页
To investigate the relation between biomarkers of inflammation and subsequent development of GCA.
3984. Genetic architecture underlying IgG-RF production is distinct from that of IgM-RF.
作者: Ai Yaku.;Yuki Ishikawa.;Takeshi Iwasaki.;Ryosuke Hiwa.;Keitaro Matsuo.;Hiroh Saji.;Kimiko Yurugi.;Yasuo Miura.;Moritoshi Furu.;Hiromu Ito.;Takao Fujii.;Taira Maekawa.;Motomu Hashimoto.;Koichiro Ohmura.;Tsuneyo Mimori.;Chikashi Terao.
来源: Rheumatology (Oxford). 2023年62卷5期2015-2020页
HLA-DRB1 alleles, particularly the shared epitope (SE) alleles, are strongly associated with RA. Different genetic structures underlie the production of the various autoantibodies in RA. While extensive genetic analyses have been conducted to generate a detailed profile of ACPA, a representative autoantibody in RA, the genetic architecture underlying subfractions of RF other than IgM-RF, namely IgG-RF, known to be associated with rheumatoid vasculitis, is not well understood.
3985. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.
作者: Nadège Cordel.;Benoît Dechelotte.;Fabienne Jouen.;Janine A Lamb.;Hector Chinoy.;Paul New.;Jiri Vencovsky.;Herman Mann.;Angeles S Galindo-Feria.;Lara Dani.;Albert Selva-O'Callaghan.;Victoria P Werth.;Adarsh Ravishankar.;Océane Landon-Cardinal.;Benoit Tressières.;Olivier Boyer.
来源: Rheumatology (Oxford). 2023年62卷4期1711-1715页
To assess the role of the anti-TIF1γ auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1γ aAb-positive adult DM.
3986. Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination.
作者: Leher Gumber.;Nancy Gomez.;Georgina Hopkins.;Davis Tucis.;Laura Bartlett.;Kieran Ayling.;Kavita Vedhara.;Graham Steers.;Mithun Chakravorty.;Megan Rutter.;Hannah Jackson.;Patrick Tighe.;Alastair Ferraro.;Sheila Power.;Marie-Josèphe Pradère.;David Onion.;Peter C Lanyon.;Fiona A Pearce.;Lucy Fairclough.
来源: Rheumatology (Oxford). 2023年62卷6期2294-2303页
Coronavirus 2019 vaccine responses in rare autoimmune rheumatic diseases (RAIRDs) remain poorly understood; in particular there is little known about whether people develop effective T cell responses. We conducted an observational study to evaluate the short-term humoral and cell-mediated T cell response after the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in RAIRD patients compared with healthy controls (HCs).
3987. SNP-based heritability estimates of gout and its subtypes determined by genome-wide association studies of clinically defined gout.
作者: Yu Toyoda.;Masahiro Nakatochi.;Akiyoshi Nakayama.;Yusuke Kawamura.;Hirofumi Nakaoka.;Kenji Wakai.;Keitaro Matsuo.;Hirotaka Matsuo.; .
来源: Rheumatology (Oxford). 2023年62卷5期e144-e146页 3988. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events.
作者: Nicola Farina.;Ruya Abdulsalam.;Thomas McDonnell.;Charis Pericleous.;Amrita D'Souza.;Vera M Ripoll.;Jemma Webster.;David A Isenberg.;Ian Giles.;Anisur Rahman.
来源: Rheumatology (Oxford). 2023年62卷6期2252-2256页
aPL are found in the blood of 20-30% of patients with SLE. Although aPL cause vascular thrombosis in the antiphospholipid syndrome, it is not clear whether positive aPL levels in early SLE increase risk of subsequent vascular events (VE). In a previous analysis of 276 patients with SLE, we found that early positivity for ≥2 of IgG anti-cardiolipin (anti-CL), IgG anti-β2-glycoprotein I (anti-β2GPI) and anti-domain I of β2-glycoprotein I (anti-DI) showed a possible association with VE. Here we have extended that analysis.
3989. Autoimmune activation and hypersensitization of the AT1 and ETA receptors contributes to vascular injury in scleroderma renal crisis.
作者: Björn Hegner.;Tobias Kretzschmar.;Nan Zhu.;Gunnar Kleinau.;Hongfan Zhao.;Julian Kamhieh-Milz.;Julia Hilger.;Ralf Schindler.;Patrick Scheerer.;Gabriela Riemekasten.;Aurélie Philippe.;Rusan Catar.
来源: Rheumatology (Oxford). 2023年62卷6期2284-2293页
Scleroderma renal crisis (SRC) is a rare vascular complication of systemic sclerosis with substantial risks for end-stage renal disease and premature death. Activating autoantibodies (Abs) targeting the angiotensin II type 1 (AT1R) and the endothelin-1 type A receptor (ETAR) have been identified as predictors for SRC. Here, we sought to determine their pathogenic significance for acute renal vascular injury potentially triggering kidney failure and malignant hypertension.
3990. Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.
作者: Franz Thiele.;Ariane Klein.;Jens Klotsche.;Daniel Windschall.;Frank Dressler.;Jasmin Kuemmerle-Deschner.;Kirsten Minden.;Ivan Foeldvari.;Dirk Foell.;Sonja Mrusek.;Prasad Thomas Oommen.;Gerd Horneff.
来源: Rheumatology (Oxford). 2023年62卷6期2230-2238页
To investigate the impact of additionally given MTX on biologic treatment of polyarticular JIA in terms of effectiveness, safety and drug survival.
3991. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region.
作者: Alain Lescoat.;Dörte Huscher.;Nils Schoof.;Paolo Airò.;Jeska de Vries-Bouwstra.;Gabriela Riemekasten.;Eric Hachulla.;Andrea Doria.;Edoardo Rosato.;Nicolas Hunzelmann.;Carlomaurizio Montecucco.;Armando Gabrielli.;Anna-Maria Hoffmann-Vold.;Oliver Distler.;Jennifer Ben Shimol.;Maurizio Cutolo.;Yannick Allanore.; .
来源: Rheumatology (Oxford). 2023年62卷6期2178-2188页
The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions worldwide. The objectives of this study were to explore the differences in terms of prevalence, phenotype, treatment and prognosis in patients with SSc-ILD from predetermined geographical regions in the EUSTAR database.
3992. Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome.
作者: Lukas Bankamp.;Beate Preuß.;Ann-Christin Pecher.;Wichard Vogel.;Jörg Henes.;Reinhild Klein.
来源: Rheumatology (Oxford). 2023年62卷6期2168-2177页
To evaluate the effect of autologous stem cell transplantation (aSCT) on functional antibodies (abs) to the angiotensin II type-1-receptor (AT1R) and topoisomerase-I (topo-I) in SSc-patients and to analyse their prognostic relevance.
3994. Nationwide racial/ethnic disparities in US emergency department visits and hospitalizations for gout.
作者: Chio Yokose.;Natalie McCormick.;Na Lu.;Amit D Joshi.;Lesley Jackson.;Minna J Kohler.;Janeth Yinh.;Yuqing Zhang.;John Hsu.;Nicola Dalbeth.;Kenneth G Saag.;Hyon K Choi.
来源: Rheumatology (Oxford). 2023年62卷6期2247-2251页
Gout prevalence is reportedly ∼20% higher in US Black adults than Whites, but racial differences in emergency department (ED) visits and hospitalizations for gout are unknown. We evaluated the latest US national utilization datasets according to racial/ethnic groups.
3997. The role of B cells in the pathogenesis of systemic sclerosis: an update.
作者: Lazaros I Sakkas.;Christina G Katsiari.;Dimitrios Daoussis.;Dimitrios P Bogdanos.
来源: Rheumatology (Oxford). 2023年62卷5期1780-1786页
The pathogenesis of SSc is incompletely understood, but several lines of evidence suggest that B cells are involved. Effector B (Beff) cells are hyperactivated and produce autoantibodies (autoAbs), and regulatory B cells (Bregs) are decreased, although a recent study reported a defect in central B cell tolerance. AutoAbs appear before fibrosis, and some have direct profibrotic effects, while others also induce microvasculopathy. Recently, a study found that B cells reactive to topo I with high affinity produce IL-6 and cause fibrosis in mice, whereas B cells with low affinity for topo I produce IL-10 and inhibit fibrosis. Ibrutinib, a Bruton's tyrosine kinase inhibitor, promoted B cells with low affinity for topo I and decreased fibrosis. These findings provide a rationale for innovative B cell-directed strategies for managing SSc, such as ibrutinib or chimeric antigen receptor T cells, particularly in the early inflammatory stage of the disease.
3999. Development of a scoring model for the Sharp/van der Heijde score using convolutional neural networks and its clinical application.
作者: Suguru Honda.;Koichiro Yano.;Eiichi Tanaka.;Katsunori Ikari.;Masayoshi Harigai.
来源: Rheumatology (Oxford). 2023年62卷6期2272-2283页
To construct a predictive model for the Sharp/van der Heijde score (SHS) and assess its applicability in clinical research settings.
4000. Similar effect of co-administration of methotrexate and folic acid for the treatment of arthritis compared to separate administration.
作者: Elisa Dalix.;Mathieu Maalouf.;Sylvie Peyroche.;Arnaud Vanden-Bossche.;Charles-Antoine Arthaud.;Sophie Hodin.;Rüdiger B Müller.;Hubert Marotte.
来源: Rheumatology (Oxford). 2023年62卷4期1706-1710页
MTX is the recommended first-line treatment for RA associated with folic acid (FA) to reduce side effects related to MTX. Here, we proposed to test a co-administration of MTX with FA in the rat adjuvant-induced arthritis (AIA) on efficacy.
|